Figure 5.

The efficacy of the combination treatment is dependent on CD8⁺ T cells. (A) BALB/c mice were inoculated with 3×10⁵ CT26-EGFR cells. On days 6–8, the mice were treated with EGF-SubA at a dose of 25 µg/kg. Photofrin was administered i.p. at a dose of 10 mg/kg on day 6. Twenty-four hours later, the tumor site was illuminated with laser light at fluence of 50 J/cm². On days 5 and 11, the mice were injected i.p. with 100 µg of anti-CD8 (YTS169) mAbs or a control antibody. (B) Mean tumor volumes (±SE). The experiment was repeated twice and a representative result is shown. Depl (depletion) describes group of mice treated with depleting mAbs and iso refers to the group treated with isotype control mAbs (n=6 for control iso and control depl, n=5 for PDT + EGF-SubA iso and n=8 for PDT + EGF-SubA depl). (C) Kaplan-Meyer plots of the survival of the mice bearing CT26-EGFR tumors. The overall survival from two combined independent experiments is shown (n=12–13). ^*P<0.05 compared with all experimental groups (Mann-Whitney test). ^#P<0.001 compared with all experimental groups (log-rank test).